Business
Matricelf Ltd. (TASE: MTLF) Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile of Its Personalized Spinal Cord Implant
Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered neural tissue implants for the treatment of spinal cord injury, today announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials.
About this update from Matricelf Ltd.
[{"type":"text","content":"NESS ZIONA, Israel, March 4, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a regenerative medicine company developing personalized engineered neural tissue implants for the treatment of spinal cord injury, today announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials.","length":396,"tagName":"p"},{"type":"text","content":"The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA.","length":173,"tagName":"p"},{"type":"text","content":"Advanced Single Nucleus RNA Sequencing Analysis","length":47,"tagName":"p"},{"type":"text","content":"Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant.","length":244,"tagName":"p"},{"type":"text","content":"The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division.","length":350,"tagName":"p"},{"type":"text","content":"Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies.","length":225,"tagName":"p"},{"type":"text","content":"Prof. Tal Dvir, CSO of Matricelf, stated, "The collective findings obtained to date support that the implant developed by the company demonstrates characteristics of maturity, stability and a promising safety profile. These data strengthen our assessment that the company's technology holds therapeutic potential for spinal cord injuries, subject to completion of advanced animal studies evaluating safety and efficacy ahead of first in human clinical trials, in accordance with regulatory requirements including those of the FDA".","length":545,"tagName":"p"},{"type":"text","content":...